UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer ...

Selecta Biosciences, Inc. (SELB) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Kevin Tan – Chief Financial Officer Carsten Brunn – President and Chief Executive Officer Peter Traber – Chief Medical Officer Kei Kishimoto – Chief Scientific Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Yun Zhong – BTIG Yatin Suneja – Guggenheim Partners John Newman – Canaccord Raju Prasad – William Blair Boobalan Pachaiyappan – H.C. Wainwright Operator Good day, and ...

| --- | --- | --- | |-------|-------|--------------------------------------------| | | | | | | | | | | | | | | | | | | | Selecta Biosciences Corporate Presentation | May 2022 Safe harbor / disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the "Company"), including without limitation, statements regarding the Company's cash runway, the unique proprietary technology platform of the Company, and the unique proprietary platform of its ...

Selecta Biosciences, Inc. (SELB) Q1 2021 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Carsten Brunn - President & Chief Executive Officer Kevin Tan - Chief Financial Officer Peter Traber - Chief Medical Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants John Newman - Canaccord Kristen Kluska - Cantor Fitzgerald Yun Zhong - BTIG Raju Prasad - William Blair Uy Ear - Mizuho Boobalan Pachaiyappan - HC Wainwright Chang Liu - Needham Operator 00:05 Good morning a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employe ...

| --- | --- | --- | |-------|-------|--------------------------------------------| | | | | | | | | | | | | | | | | | | | Selecta Biosciences Corporate Presentation | April 2022 Safe harbor / disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the "Company"), including without limitation, statements regarding the Company's ability to complete the proposed offering on favorable terms or at all, the anticipated use of proceeds of the p ...

Selecta Biosciences, Inc. (SELB) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Carsten Brunn - President, CEO Kevin Tan - CFO Peter Traber - CMO Conference Call Participants Kristen Kluska - Cantor Fitzgerald John Newman - Canaccord Raju Prasad - William Blair Uy Ear - Mizuho Boobalan Pachaiyappan - Operator Good morning. And welcome to the Selecta Biosciences Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update Conference Call. Currently, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 65 Grove Street, Watertown, MA ...

Selecta Biosciences Corporate Presentation SELB January 2022 Safe harbor / disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and pegloticase and related data readouts, the potential of ImmTOR™ to reduce AAV vector immunogenicity and enable redosin ...

Selecta Biosciences, Inc. (SELB) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Kevin Tan - Chief Financial Officer Carsten Brunn - President and CEO Peter Traber - Chief Medical Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Raju Prasad - William Blair Gil Blum - Needham & Company Shu Zhiqiang - BTIG Operator Good morning. And welcome to the Selecta Biosciences Third Quarter 2021 Financial Results and Corpo ...